Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
Other Sizes |
|
ln Vitro |
By attaching itself to the 23S rRNA of the 50S subunit of bacterial ribosomes, tylosin tartrate binds to bacteria and has antibacterial properties [1]. Additionally, Gram-negative bacteria of Mycobacterium haemolyticus 11935, Pseudomonas multocida 4407, and E. coli are inhibited from growing by tylosin tartrate. bacteria ATCC 25922 and E. coli AS19rlmAI, in that order [3].
|
---|---|
ln Vivo |
In rats treated with lipopolysaccharide (LPS), tylosin tartrate (10–500 mg/kg; subcutaneous injection) typically lowers increased TNF-α and IL-1β levels and enhances IL-10 levels [4].
|
Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse (2-3 months old, 20-25 g) [4]
Doses: 10 mg/kg, 100 mg/kg, 500 mg/kg Route of Administration: subcutaneous injection Experimental Results: diminished increase In mice treated with TNF-α LPS (250 µg), IL-1β and IL-1β levels were elevated, but IL-10 levels were increased. |
References |
[1]. Mingfu Liu, et al. Resistance to the macrolide antibiotic tylosin is conferred by single methylations at 23S rRNA nucleotides G748 and A2058 acting in synergy. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23): 14658–14663.
[2]. Carlo Pinna, et al. In Vitro Evaluation of the Effects of Tylosin on the Composition and Metabolism of Canine Fecal Microbiota. Animals (Basel). 2020 Jan; 10(1): 98. [3]. Niels Møller Andersen, et al. Inhibition of Protein Synthesis on the Ribosome by Tildipirosin Compared with Other Veterinary Macrolides. Antimicrob Agents Chemother. 2012 Nov; 56(11): 6033–6036. [4]. Ayse Er, et al. Effects of tylosin on serum cytokine levels in healthy and lipopolysaccharide-treated mice. Acta Vet Hung. 2010 Mar;58(1):75-81. |
Molecular Formula |
C50H83NO23
|
---|---|
Molecular Weight |
1066.1869
|
CAS # |
74610-55-2
|
Related CAS # |
Tylosin;1401-69-0;Tylosin phosphate;1405-53-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O1[C@]([H])(C([H])([H])[H])[C@]([H])([C@@]([H])([C@]([H])([C@]1([H])O[C@]1([H])[C@@]([H])(C([H])([H])[H])[C@@]([H])(C([H])([H])C(=O)O[C@]([H])(C([H])([H])C([H])([H])[H])[C@]([H])(C([H])=C(C([H])([H])[H])C([H])=C([H])C([C@]([H])(C([H])([H])[H])C([H])([H])[C@]1([H])C([H])([H])C([H])=O)=O)C([H])([H])O[C@@]1([H])[C@@]([H])([C@@]([H])([C@@]([H])([C@@]([H])(C([H])([H])[H])O1)O[H])OC([H])([H])[H])OC([H])([H])[H])O[H])O[H])N(C([H])([H])[H])C([H])([H])[H])O[C@@]1([H])C([H])([H])[C@](C([H])([H])[H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])O[H].O([H])[C@@]([H])(C(=O)O[H])[C@]([H])(C(=O)O[H])O[H] |c:45,52|
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~93.79 mM)
DMSO : ≥ 100 mg/mL (~93.79 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (93.79 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.9379 mL | 4.6896 mL | 9.3792 mL | |
5 mM | 0.1876 mL | 0.9379 mL | 1.8758 mL | |
10 mM | 0.0938 mL | 0.4690 mL | 0.9379 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.